Patents by Inventor SVEN NYLANDER

SVEN NYLANDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO TICAGRELOR AND METHODS OF USE
    Publication number: 20240101712
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: August 17, 2023
    Publication date: March 28, 2024
    Inventors: Andrew BUCHANAN, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • COMBINATION TREATMENT
    Publication number: 20240026318
    Abstract: The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by administrating a recombinant apyrase protein in conjunction with a P2Y12 inhibitor.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 25, 2024
    Inventors: Leif CARLSSON, Sven NYLANDER, Ola FJELLSTROM, Lina BADIMON MAESTRO
  • Antibodies to ticagrelor and methods of use
    Patent number: 11773186
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: October 3, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • COMBINATION TREATMENT
    Publication number: 20220073888
    Abstract: The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by administrating a recombinant apyrase protein in conjunction with a P2Y12 inhibitor.
    Type: Application
    Filed: August 18, 2021
    Publication date: March 10, 2022
    Inventors: Leif CARLSSON, Sven NYLANDER, Ola FJELLSTROM, Lina BADIMON MAESTRO
  • ANTIBODIES TO TICAGRELOR AND METHODS OF USE
    Publication number: 20210371546
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: February 16, 2021
    Publication date: December 2, 2021
    Inventors: Andrew BUCHANAN, Sven NYLANDER, Mark PENNEY, Philip NEWTON, Feenagh KEYES, Tord INGHARDT
  • Antibodies to ticagrelor and methods of use
    Patent number: 10954308
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: March 23, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • Antibodies to ticagrelor and methods of use
    Patent number: 10487154
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 26, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • ANTIBODIES TO TICAGRELOR AND METHODS OF USE
    Publication number: 20190077882
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: July 16, 2018
    Publication date: March 14, 2019
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • ANTIBODIES TO TICAGRELOR AND METHODS OF USE
    Publication number: 20180319897
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 8, 2018
    Inventors: Andrew BUCHANAN, Sven NYLANDER, Mark PENNEY, Philip NEWTON, Feenagh KEYES, Tord INGHARDT
  • Antibodies to ticagrelor and methods of use
    Patent number: 9982061
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: May 29, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • ANTIBODIES TO TICAGRELOR AND METHODS OF USE
    Publication number: 20160130366
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: September 30, 2015
    Publication date: May 12, 2016
    Inventors: ANDREW BUCHANAN, SVEN NYLANDER, MARK PENNEY, PHILIP NEWTON, FEENAGH KEYES, TORD INGHARDT